Suppr超能文献

由人血清白蛋白制备用于生产固体剂型的中间产品的配方。

Formulation of an intermediate product from human serum albumin for the production of a solid dosage form.

作者信息

Kristó Katalin, Bajdik János, Eros István, Dékány Imre, Pallai Zsolt, Pintye-Hódi Klára

机构信息

Department of Pharmaceutical Technology, University of Szeged, Szeged, Hungary.

出版信息

Eur J Pharm Biopharm. 2008 Mar;68(3):741-6. doi: 10.1016/j.ejpb.2007.07.002. Epub 2007 Sep 17.

Abstract

The main objective of this study was to evaluate and to increase the processibility of a model protein (human serum albumin (HSA)) for preparation of an intermediate for a solid dosage form. The applicability of the solid forms is easier, and therefore their formulation is a promising method for the application of proteins. The layering of powdered cellulose with HSA solutions of different concentrations in a fluid bed apparatus with the top spray method was applied. The yield of this technique was very good, independently of the concentration of the applied solution. The HSA covered the particles (the HSA layer formed was smooth), but it caused aggregation of the cellulose particles, and spray-dried microparticles also formed. The proportion of optimum-sized particles (200-315 microm) decreased. The largest amount was detected for the samples prepared with liquid containing 15% HSA (about 2 times higher than the second best). Not only the size, but also the shape of the particles was changed. The alteration in this parameter caused a change in the flowability. This was likewise the best for the samples prepared with the liquid containing 15% HSA. The concentration of HSA in the fraction containing smaller particles was higher, because of the abrasion of the particles and the enrichment of the spray-dried HSA. The distribution of HSA in the large particles was uneven. The layering of powder cellulose can be applied to produce an intermediate from HSA for solid dosage forms, but the appropriate concentration of this protein solution must be optimized previously because HSA can act as a binder. The formation of large agglomerates must be eliminated, because the distribution of the active agent in these is very inhomogeneous. The present results indicated that the best value can be achieved with liquid containing between 12.5% (most homogeneous distribution of HSA) and 15% HSA (best flowability).

摘要

本研究的主要目的是评估并提高一种模型蛋白(人血清白蛋白(HSA))的可加工性,以制备固体剂型的中间体。固体形式的适用性更强,因此其制剂是蛋白质应用的一种有前景的方法。采用顶喷法在流化床装置中将不同浓度的HSA溶液与粉状纤维素进行分层。该技术的产率很高,与所应用溶液的浓度无关。HSA覆盖了颗粒(形成的HSA层很光滑),但导致了纤维素颗粒的聚集,同时也形成了喷雾干燥的微粒。最佳尺寸颗粒(200 - 315微米)的比例下降。用含15% HSA的液体制备的样品检测到的量最大(约为第二优样品的2倍)。不仅颗粒尺寸发生了变化,颗粒形状也改变了。这一参数的改变导致了流动性的变化。对于用含15% HSA的液体制备的样品,流动性同样最佳。由于颗粒的磨损和喷雾干燥的HSA的富集,较小颗粒部分中HSA的浓度较高。HSA在大颗粒中的分布不均匀。粉状纤维素的分层可用于从HSA制备固体剂型的中间体,但必须预先优化该蛋白质溶液的合适浓度,因为HSA可作为粘合剂。必须消除大团聚物的形成,因为活性剂在其中的分布非常不均匀。目前的结果表明,含12.5%(HSA分布最均匀)至15% HSA(流动性最佳)的液体可获得最佳值。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验